When comparing Smurf2 expression in patients with liver metastases and patients with stage II or III CRC (i.e., without any distant metastases), high Smurf2 expression was observed in 47.0% of patients with liver metastases and 73.3% of patients with stage II or III CRC. Here, SMURF2 is linked to colorectal carcinoma.